fr   en

Browse by date
Or search by keyword
Date: 2010-08-18
Biotech partner: CEVEC Pharmaceuticals (Germany) Life Technologies Corporation (USA)
Type of agreement: * licensing
Compound: Human CAP-T® Technology The CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.
Nature of the agreement: CEVEC Pharmaceuticals has signed a co-exclusive worldwide licensing agreement with Life Technologies Corporation. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells. Life Technologies combines CEVEC’s proprietary protein expression system based on CAP cells with its tailored protein expression product portfolio (media, transfection reagents etc.) to enable research scientists worldwide to achieve highest yield and quality protein expression.
Financial terms of the agreement: Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed.

Go back to previous page